Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension: Statistical and Health Economic Analysis Plan for the 65 trial

Thomas, Karen; Patel, Akshay; Sadique, M Zia; Grieve, Richard D; Mason, Alexina J; Moler, Silvia; Gordon, Anthony C; Rowan, Kathryn M; Mouncey, Paul R; Lamontagne, Francois; +1 more... Harrison, David A; (2019) Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension: Statistical and Health Economic Analysis Plan for the 65 trial. Journal of the Intensive Care Society. p. 175114371986038. ISSN 1751-1437 DOI: https://doi.org/10.1177/1751143719860387

Abstract

The 65 trial is a pragmatic, multicentre, parallel-group, open-label, randomised clinical trial of permissive hypotension (targeting a mean arterial pressure target of 60–65 mmHg during vasopressor therapy) versus usual care in critically ill patients aged 65 years or over with vasodilatory hypotension. The trial will recruit 2600 patients from 65 United Kingdom adult general critical care units. The primary outcome is all-cause mortality at 90 days. An economic evaluation is embedded. This paper describes the proposed statistical and health economic analysis for the 65 trial.

Additional Information

Item Type	Article
Faculty and Department	Faculty of Public Health and Policy > Dept of Health Services Research and Policy Faculty of Epidemiology and Population Health > Dept of Medical Statistics
Elements ID	134517